ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset
Agreement expands collaboration between ProBio's biologics discovery capabilities and AbTis' site-specific antibody-drug conjugate technology HOPEWELL, N.J., Nov. 10, 2026 /PRNewswire/ -- ProBio, a global contract research, development, and manufacturing organization (CRDMO), today...
Covered in this story
Call it yourself
No calls on $ADC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Agree Realty →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.